NEUROKINE
Initial Training Network for Neurogical disorders orchestrated by cytoKines
| Coordinatore | UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Organization address
address: Langenbeckstrasse 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙536˙795 € |
| EC contributo | 3˙536˙795 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Organization address
address: Langenbeckstrasse 1 contact info |
DE (Mainz) | coordinator | 666˙616.50 |
| 2 |
UNIVERSITAET ZUERICH
Organization address
address: Raemistrasse 71 contact info |
CH (ZURICH) | participant | 551˙009.80 |
| 3 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 469˙709.40 |
| 4 |
APITOPE TECHNOLOGY (BRISTOL) LTD
Organization address
address: "Bristol & Bath Science Park, Dirac Cresent, Emersons Green" contact info |
UK (BRISTOL) | participant | 288˙906.62 |
| 5 |
UNIVERSITA VITA-SALUTE SAN RAFFAELE
Organization address
address: Via Olgettina 58 contact info |
IT (MILANO) | participant | 244˙687.95 |
| 6 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 244˙051.72 |
| 7 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 240˙711.45 |
| 8 |
WEIZMANN INSTITUTE OF SCIENCE
Organization address
address: HERZL STREET 234 contact info |
IL (REHOVOT) | participant | 228˙463.84 |
| 9 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 225˙918.88 |
| 10 |
MILTENYI BIOTEC GMBH
Organization address
address: FRIEDRICH EBERT STRASSE 68 contact info |
DE (BERGISCH GLADBACH) | participant | 146˙950.55 |
| 11 |
BIONTECH AG
Organization address
address: HOLDERLINSTRASSE 8 contact info |
DE (Mainz) | participant | 114˙884.44 |
| 12 |
PHENEX PHARMACEUTICALS AG
Organization address
address: DONNERSBERGWEG 1 contact info |
DE (LUDWIGSHAFEN) | participant | 114˙884.44 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Neuroinflammatory disease, in particular multiple sclerosis affects more than 700.000 people within Europe alone. European countries are at the forefront of neuroimmunological research and students in medicine and biology are greatly attracted by the field. Neuroimmunology research further impacts our understanding of the ethiopathology of other CNS-disorders including Alzheimer’s Dementia and Morbus Parkinson. The ability of inflammatory immune cells to cause tissue damage within the nervous system is largely governed by soluble mediators including cytokines/chemokines, cytolytic molecules and growth factors. The therapeutic targeting of such mediators has proven successful for the treatment of a number of inflammatory diseases, yet is failing for the treatment of neuroinflammatory disorders. Clearly, the rules and regulatory elements, which govern inflammation and tissue injury within the CNS, differ significantly from those of other tissues and a unique CNS-focused research approach to unravel these rules is required. In this ITN proposal, we will train ESRs and ERs specifically in Neuroimmunology by combining prominent laboratories in academia and industry on the task to study the communication networks between immune and CNS-resident cells. Scientifically, we focus particularly on the soluble factors mediating cell-cell communication at the immune-CNS interface. To this end, we combine expertise in molecular and cellular Neuroimmunology with Neuropathology of human and animal models of CNS inflammation. In addition, our goal is to further utilize inflammatory processes for neuroprotection.'